Stocks To Buy Now Blog

All posts by Christopher

Greenland Mines Ltd. (NASDAQ: GRML) Advances Critical Minerals Strategy as Global Demand Accelerates

  • The growing focus on critical minerals reflects their importance across nearly every major industrial sector.
  • Greenland Mines was established with the objective of building a diversified portfolio of critical minerals projects within Greenland.
  • The company is also pursuing strategic acquisitions and partnerships designed to expand its position within the critical minerals sector.

Critical minerals have become one of the defining strategic resources of the modern economy, underpinning everything from electric vehicles and renewable energy systems to advanced semiconductors and national defense technologies. As governments and industries work to strengthen supply chains and reduce dependence on foreign sources of essential raw materials, Greenland Mines (NASDAQ: GRML) is positioning itself to build a diversified critical minerals platform centered on Greenland’s extensive mineral resources.

The growing focus on critical minerals reflects their importance across nearly every major industrial sector. The U.S. Geological Survey defines critical minerals as nonfuel minerals that are essential to economic or national security and whose supply chains are vulnerable to disruption. These materials, including rare earth elements, graphite, nickel, copper, cobalt, lithium, titanium, niobium, tantalum and others, play indispensable roles in advanced manufacturing, aerospace, electronics, clean energy technologies and military systems. As demand continues to grow, securing reliable and diversified supplies has become a priority for governments around the world.  

The International Energy Agency has reported that the transition toward cleaner energy technologies is expected to drive substantial long-term increases in demand for many critical minerals. Electric vehicles require significantly larger quantities of mineral inputs than conventional automobiles, while renewable power generation, battery storage systems and modern electrical grids all depend on secure supplies of specialized metals and minerals. At the same time, artificial intelligence infrastructure, advanced computing, telecommunications and semiconductor manufacturing continue expanding demand for copper and other strategic materials.

Recognizing these challenges, the United States and other allied nations have launched initiatives to strengthen domestic and partner-country supply chains for critical minerals. Greenland has emerged as one of the regions attracting increasing attention because of its substantial geological potential and strategic location. According to the Geological Survey of Denmark and Greenland, the island hosts significant deposits of rare earth elements, graphite, molybdenum, titanium, nickel, platinum group metals and other mineral resources considered important to future industrial and technological development. 

Greenland Mines was established with the objective of building a diversified portfolio of critical minerals projects within Greenland. According to the company, its strategy focuses on identifying, acquiring and advancing high-potential mineral assets that can contribute to more secure global supply chains while supporting the growing demand for strategic resources. The company believes Greenland’s favorable geology and expanding international interest in resource development create an attractive environment for long-term exploration and project development. 

The company’s portfolio includes exploration projects prospective for several commodities identified as strategically important by governments and industry. Greenland Mines has stated that it is pursuing opportunities across multiple critical mineral categories rather than relying on a single commodity, an approach intended to provide broader exposure to long-term trends driving demand for advanced materials. Through exploration, geological evaluation and project advancement, the company aims to establish a platform capable of supporting future resource development as global markets continue evolving. 

The company is also pursuing strategic acquisitions and partnerships designed to expand its position within the critical minerals sector. Rather than focusing solely on individual exploration properties, management has outlined a broader vision of creating an integrated critical minerals platform that can capitalize on Greenland’s emerging importance as a source of strategically significant resources. The company’s investor materials indicate that this strategy is intended to provide flexibility as market conditions and mineral demand continue to evolve.  

An important aspect of Greenland Mines’ strategy is its emphasis on operating within a jurisdiction that has attracted increasing international interest from governments seeking diversified mineral supply chains. As concerns over resource security have intensified, Greenland has become the focus of numerous public and private initiatives aimed at responsibly developing its mineral potential. The company’s management believes that establishing an early presence in the region positions Greenland Mines to participate in what could become a significant long-term expansion of critical minerals production. 

Beyond exploration activities, Greenland Mines has emphasized its commitment to responsible resource development and creating long-term value through disciplined project evaluation. The company has stated that it intends to advance projects through systematic geological work while evaluating opportunities that align with evolving market demand for critical minerals used in clean energy, advanced manufacturing and national security applications. 

The strategic importance of critical minerals is expected to continue increasing as countries modernize infrastructure, expand renewable energy generation, invest in artificial intelligence and strengthen domestic manufacturing capabilities. Meeting those needs will require new sources of responsibly developed mineral resources and diversified supply chains capable of supporting long-term industrial growth. Against that backdrop, Greenland Mines is working to establish itself as a participant in one of the world’s most significant emerging critical minerals regions. By assembling a portfolio of prospective mineral assets and pursuing a broader platform strategy, the company is seeking to position itself alongside one of the most important long-term trends shaping the global mining industry.

For more information, visit www.GreenlandMines.com.

NOTE TO INVESTORS: The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML

Frontieras North America Inc. Advances Coal Innovation Amid New Federal Investment

  • A newly released federal funding package is designed to support coal-fired power generation, coal exports and new coal infrastructure projects across the United States.
  • Frontieras North America is commercializing its patented FASForm(TM) Solid Carbon Fractionation technology, which separates coal into multiple valuable outputs through a continuous-feed process.
  • Frontieras is also currently advancing the first commercial-scale deployment of the technology in Mason County, West Virginia.

The Trump administration’s announcement earlier this month of nearly $700 million in new federal support for the U.S. coal industry has renewed attention on coal’s role in the nation’s energy and industrial future. Among the companies operating in the sector, Frontieras North America is pursuing a different approach to coal utilization through its proprietary FASForm technology, which is designed to convert coal into multiple high-value products rather than simply burning it for electricity.

The funding package is designed to support coal-fired power generation, coal exports and new coal infrastructure projects across the United States. The administration will use authority under the Defense Production Act to support 13 coal-fired power plants, help construct new coal plants in Alaska and West Virginia, restart a shuttered coal plant in Maryland and assist development of a coal export terminal in Oakland, California. The White House said the initiative is expected to support or create more than 14,000 jobs across coal, construction, rail and maritime industries.

Administration officials have linked the initiative to growing U.S. electricity demand, particularly from artificial intelligence (“AI”) infrastructure, advanced manufacturing and data centers. Reports indicate that more than $360 million of the funding is expected to be directed toward power-plant modernization projects, while additional funding will support new coal facilities and export infrastructure. The administration has stated that preserving reliable baseload power generation is increasingly important as electricity consumption rises.

The announcement represents the latest effort to reverse the long-term decline of the domestic coal industry. According to the U.S. Energy Information Administration, coal generated approximately 15% of U.S. electricity in 2024, down significantly from previous decades as natural gas and renewable energy sources expanded their market share. Even so, coal remains one of the nation’s most abundant energy resources, with the United States possessing some of the world’s largest recoverable coal reserves.

For Frontieras North America, the renewed federal focus on coal highlights a broader opportunity. The company is commercializing its patented FASForm Solid Carbon Fractionation technology, which separates coal into multiple valuable outputs through a continuous-feed process. According to the company, the technology produces refined liquid fuels, hydrogen, FASCarbon(TM) — the company’s purified solid carbon product — ammonium sulfate fertilizer and sulfuric acid  from coal feedstocks. Rather than treating coal as a single-use fuel source, the process is designed to extract multiple marketable products from the same ton of coal.

The company’s strategy is based on the premise that coal contains a wide range of valuable hydrocarbons and industrial materials that have historically been underutilized. The company’s FASForm(TM) platform maximizes the economic value contained within coal while generating multiple revenue streams from a single feedstock.

Frontieras is also currently advancing the first commercial-scale deployment of the technology in Mason County, West Virginia. State officials have described the project as an approximately $850 million investment that will transform coal into fuels, fertilizers and industrial carbon products. The location offers direct access to Appalachian coal reserves, river transportation and rail infrastructure, positioning the facility near both feedstock supplies and industrial markets.

The company’s recent initiatives also extend beyond product manufacturing. Earlier this year, Frontieras completed feasibility engineering for FASGEN(TM), a platform designed to support coal-fired power generation while creating additional fuel and chemical products from coal resources. The company has positioned the platform as a way to preserve and expand the value of existing coal assets as energy demand increases.

Frontieras North America’s technology-driven approach aligns with a growing industry discussion centered not only on coal production but also on how the resource can be utilized more completely. If federal support succeeds in strengthening the broader coal ecosystem, Frontieras and other companies developing new methods to transform coal are positioned to benefit.

For more information about Frontieras, visit the company’s website at www.Frontieras.com.

NOTE TO INVESTORS: The latest news and updates relating to Frontieras are available in the company’s newsroom at https://ibn.fm/Frontieras

CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) Implementing Plan to Assess Underground Resource and Exploit Above-Ground Stockpile at Clayton Property in Idaho

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid advertising.

  • CMX’s Clayton Silver Project in Idaho is a historic mine that produced silver, zinc, copper, lead, and gold between 1935 and 1986
  • Due to the small scale of mining operations, the Clayton ore bodies were never fully mined, while mined material at grades considered too low was left unprocessed, creating a stockpile
  • The stockpile and the unexplored mine represent significant exploitation potential for the company
  • CMX plans to install an ore-sorting system on site to process the stockpile, which potentially holds 1,000,000 tons or more of mineralized material
  • The company is also implementing a work program that includes site preparation, geophysical survey, drilling and staking, to help assess the full potential of the underground resource

Silver is widely used in industrial and non-industrial applications, from the manufacture of electronics, water purifiers, and photovoltaics to jewelry and silverware. The panoply of use cases created a demand of 1.13 billion ounces in 2025, according to the Silver Institute’s World Silver Survey 2026, against a documented supply of 1.09 billion ounces (https://ibn.fm/iO2ky). (Mine production accounted for 846.6 million ounces.) The demand-supply deficit is projected to grow even further, representing an opportunity that CMX Gold & Silver (CSE: CXC) (OTC: CXXMF) intends to exploit. CMX, through its wholly owned U.S. subsidiary, holds a 100% interest in the historic Clayton Silver Mine in the Bayhorse Mining District of Idaho.

Discovered in the late 1800s, Clayton was operationalized in 1935, with production continuing through 1986, when low prices forced closure. During those five decades, the operator mined an estimated 2,145,652 tons of ore, which, upon processing, produced 218,692 kg (7,031,110 oz) silver, 39,358,903 kg (86,771,527 lbs.) lead, 12,778,700 kg (28,172,211 lbs.) zinc, 754,858 kg (1,664,177 lbs.) copper, and 67 kg (2,154 oz) gold. At current spot metals prices, this historic output is valued at over US$600 million.

Small scale mining meant certain mineralized zones were left unexplored and operations only partially accessed ore from two major ore bodies, the North and South. For instance, hole 1501-A, which was drilled in the mid-1960s, penetrated the mineralized zone at a depth that was approximately 300 feet below the deepest underground development. At this depth, the hole “intercepted 22 feet (6.70 m) of 4.07 oz Ag/t, 5.75% lead, and 5.37% zinc.” The true width, however, remains unknown.

The Clayton Mine’s unexploited resources represent a boon for CMX. In the management’s discussion and analysis (“MD&A”), released April 17, 2026, the company noted that “mineralization is open to the north, the south, and to depth, all of which is untested. For example, there is potential for resources to exist at shallower depths below and adjacent to the South Ore Body.” (https://ibn.fm/dJk6l)

In addition to the unmined resources, mined material was left unprocessed when the grade was considered low, with the operator heaping it into a stockpile. But as CMX confirmed through a 2022 sampling program and analysis, the stockpile has exploitation potential. According to a 2023 press release announcing details of the analysis, assay results confirmed that the ore-sorting technology was viable for processing the stockpile, which is estimated to contain 1,000,000 tons or more of mineralized material. The initial test of the stockpile material recovered over 70% of the silver, lead, and zinc in ore-sorted product equal to 10% of the original mass (https://ibn.fm/CYPXb).

Based on these results, the company plans to assemble an ore sorting system at the Clayton mine capable of processing 3,000-4,000 tons of material per day, according to the MD&A. The ore-sorting of the historical stockpile forms part of the company’s plan to generate future cash flow. The company also intends to proceed with other work programs, including geophysics, drilling, and preliminary engineering on the refurbishment of the mill. It is currently finalizing an equity offering to fund the planned 2026 geophysical survey and drill program, which will begin assessing the underground resource potential.

For company information, visit the company’s website at www.CMXGoldandSilver.com.

NOTE TO INVESTORS: The latest news and updates relating to CXXMF are available in the company’s newsroom at https://ibn.fm/CXXMF

The Next Battle in Space Isn’t Launching Satellites. It’s Managing Them.

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) and may include paid advertising.

  • SpaceX’s record June 2026 IPO put a public spotlight on space, yet most of the sector’s frontier companies remain private and out of reach for public investors
  • Antaris, a software-defined space infrastructure company backed by Planet Ventures, signed a memorandum of agreement with Transcelestial to develop and flight-test a combined surveillance and optical-communications architecture on its JANUS-2 mission in late 2026
  • Planet Ventures gives public-market investors exposure to private space companies such as Antaris, Relativity Space, and General Astronautics that are typically accessible only to venture and institutional capital

The biggest story in space this year did not happen in orbit. On June 12, 2026, SpaceX completed the largest initial public offering in history, pricing at $135 per share and debuting at a valuation approaching $1.8 trillion. For the first time, everyday investors could buy a direct stake in the company that drove launch costs lower and reshaped the economics of space.

Yet the listing also exposed a gap. SpaceX is now public, but many of the companies building the next layer of space economy remain private and largely inaccessible to public-market investors. While rockets captured the first chapter of commercial space development, the next phase is increasingly focused on software, communications, robotics, and the infrastructure required to manage rapidly growing networks of satellites and space-based systems.

Closing that gap is the strategy behind Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF), an investment issuer focused on providing shareholders with exposure to private companies operating across multiple segments of the expanding space economy. One of those portfolio companies recently achieved a milestone that highlights where the industry may be heading next.

The Operating System for Space

Antaris, a private space technology company backed by Planet Ventures, is building a software-defined platform for designing, simulating, deploying, and operating satellite missions. Rather than focusing on a single spacecraft or payload, the company’s technology is intended to simplify how entire constellations are built and managed across multiple hardware providers and orbital environments.

The concept mirrors the evolution of cloud computing on Earth. As digital infrastructure became increasingly complex, software platforms emerged to simplify deployment, management, and scalability. Antaris is applying a similar approach to space operations, where satellite operators increasingly require flexible software capable of managing missions across diverse systems and suppliers.

Investors have taken notice. Antaris completed a $28 million Series A financing and counts investors including Lockheed Martin Ventures and WestWave Capital among its backers. The company’s mission is straightforward: make space infrastructure easier to build, deploy, and operate.

A Strategic Milestone for Antaris

That vision moved forward on May 6, 2026, when Antaris announced a memorandum of agreement with Transcelestial, a company developing advanced optical communications technology designed to move data between satellites at high speed.

Together, the companies plan to develop and demonstrate persistent intelligence, surveillance, and reconnaissance (“ISR”) architecture integrated with high-throughput optical communications in low Earth orbit. The initiative is expected to be flight-validated aboard Antaris’ JANUS-2 mission, currently targeted for the fourth quarter of 2026.

The agreement highlights a broader shift underway across the space economy. The challenge is no longer simply putting sensors into orbit. Modern satellite networks must collect, process, transmit, and act upon enormous volumes of information in near real time. As constellations expand and applications become more sophisticated, software and communications infrastructure increasingly become the critical layer that enables everything else.

Optical communications have attracted growing interest because they can transmit significantly more data than traditional radio-frequency systems while reducing latency and improving security. Combined with persistent sensing capabilities, these technologies could support real-time decision-making across commercial, government, and defense applications.

For Antaris, the Transcelestial agreement represents validation that software-defined mission management and high-speed communications are becoming foundational components of next-generation space infrastructure.

A Different Way to Invest in the Space Economy

The SpaceX IPO reinforced a challenge many investors face: some of the most innovative companies in the industry remain private. Access is often limited to venture capital firms, institutional investors, and specialized private funds.

Planet Ventures has built its strategy around addressing that gap. Rather than operating a single technology business, the company invests across multiple segments of the space economy, including launch systems, mission-management software, orbital infrastructure, robotics, and emerging aerospace technologies.

Its portfolio includes investments in Antaris, General Astronautics, Mantis Space, and other developing space-focused businesses. Collectively, those investments provide exposure to multiple layers of the commercial space ecosystem rather than a single technology theme.

The opportunity is substantial. According to World Economic Forum estimates, the global space economy was valued at approximately $630 billion in 2025 and is projected to exceed $1.8 trillion by 2035. The Space Foundation estimates that commercial activity already accounts for roughly 78% of the sector, highlighting the growing role of private enterprise in shaping the future of space.

Building the Infrastructure Behind the Headlines

Space headlines often focus on rocket launches, lunar missions, and billionaire founders. SpaceX’s historic IPO fit squarely into that narrative. Yet history suggests that some of the most durable value creations occur in the infrastructure layer that enables those headline-grabbing achievements to scale.

As satellite deployments accelerate and mission complexity continues to increase, the platforms responsible for coordinating communications, operations, and decision-making may become as important to the space economy as operating systems are to personal computing.

The JANUS-2 mission remains ahead, and the companies within Planet Ventures’ portfolio are still executing early-stage growth strategies. Yet SpaceX’s public debut may have reinforced a simple reality: much of the next decade’s value creation in space is likely still occurring behind private-company doors. Planet Ventures’ strategy is built around gaining exposure to those opportunities before they become household names.

For more information, visit www.PlanetVenturesInc.com.

NOTE TO INVESTORS: The latest news and updates relating to PNXPF are available in the company’s newsroom at https://ibn.fm/PNXPF

Disclaimer

Investor Brand Network (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Planet Ventures Inc. will make aggregate payments of $100,000  to us to provide marketing services for a term of 1 year. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of applicable securities legislation. Such statements include, without limitation, statements regarding: Planet Ventures’ investment strategy and objectives; anticipated developments in the commercial space industry, including the growth of orbital energy and space robotics markets; the projected growth of the global space economy; Planet Ventures’ expectations regarding the strategic importance of its investments in Mantis Space and General Astronautics; the anticipated role of orbital energy technologies and robotic servicing systems in future in-orbit operations; and the potential for these technologies to become foundational to the next generation of commercial space activity.

Forward-looking statements are not guarantees of future performance. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this document are made as of the date hereof and Planet Ventures undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

Risk Factors

Investing in Planet Ventures and its portfolio companies involves a high degree of risk. The following is a summary of key risk factors. This is not an exhaustive list, and additional risks may exist that are not currently known:

  • Early-Stage Investment Risk. Portfolio companies have limited operating histories and are pre-revenue. Investments are speculative and may result in a total loss of capital.
  • Technology Risk. The orbital energy and lunar habitation technologies underlying the Company’s investments are unproven at commercial scale and may not be successfully developed or deployed.
  • Regulatory Risk. Space sector operations require licenses and approvals from domestic and international regulatory bodies. Failure to obtain or maintain these could materially delay or prevent operations.
  • Market Risk. Commercial demand for in-space power systems and lunar services has not been established at scale. Projected market growth may not be realized within anticipated timeframes.
  • Liquidity Risk. Investments in private, early-stage companies are illiquid. There is no guarantee of a market for these securities or the ability to exit on favorable terms.
  • Capital Risk. Portfolio companies may require additional funding that may not be available, or may be available only on dilutive or restrictive terms.
  • Macroeconomic and Geopolitical Risk. Adverse macroeconomic conditions or geopolitical developments could disrupt the Company’s investment strategy or the operations of portfolio companies.
  • Key Personnel Risk. The Company’s performance depends in part on retaining key personnel and advisors. Loss of key individuals could adversely affect the Company’s operations and investment activities.

About InvestorWire

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Advances Santa Fe, Walker Lane amid Tightening Gold Supply Dynamics

Disseminated on behalf of  Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.

  • Top gold-producing countries are showing strain of widespread government, cost and environmental pressures.
  • These pressures strengthen the case for secure, transparent and infrastructure-supported gold development in the United States.
  • Existing mine infrastructure, historical production, oxide material and location in a leading U.S. gold state may give Lahontan’s Santa Fe project a different development profile.

Global gold supply is entering a more complicated era, shaped not only by geology and discovery rates but also by government policy, rising operating costs, safety enforcement, environmental oversight and growing pressure for producing countries to capture more value at home. In that setting, Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF), a Canadian mineral exploration company with four gold and silver exploration properties in Nevada’s Walker Lane, is advancing the Santa Fe Mine project and related assets in one of the United States’ most established gold-producing jurisdictions.

The pressure is visible even in the world’s largest producing country. The U.S. Geological Survey noted that China, Russia, Australia, Canada and the United States were the leading gold producers in 2025, in descending order, and together accounted for 41% of estimated global output. Yet China’s own production base showed strain in early 2026. Reuters reported that China’s total gold production from domestic and imported raw materials was 136.230 metric tons in the first quarter of 2026, down 3.3% year over year, while domestic production fell 7.1% to 81.065 metric tons. The report cited the China Gold Association and noted that the decline came “as safety inspections led some smelters to suspend production for maintenance.”

That kind of decline matters because it suggests supply growth can be constrained even when gold prices are high. Safety reviews, environmental regulation, mine depletion and maintenance-related disruptions can all limit production from mature districts. For investors and operators, the result is a market in which the availability of ounces may depend less on price alone and more on whether projects are in jurisdictions with clear rules, existing infrastructure and realistic pathways to development.

At the same time, many resource-rich countries are revisiting the economics of mining in response to high gold prices. Ghana, Africa’s top gold producer, has become a clear example. Earlier this year, Reuters reported that Ghana planned to scrap long-term mining investment stability agreements and double royalties under broad mining-sector reforms. The proposed structure would raise royalties from the current 3–5% range to 9–12%, with the top rate applying if gold reaches $4,500 per ounce or higher. The reforms also include tougher local-content rules, and Reuters quoted Ghana Minerals Commission acting CEO Isaac Tandoh as saying, “Renewal is conditional, not automatic.”

The local-content trend has also continued. Ghana’s mining regulator has given international companies including Newmont, AngloGold Ashanti and Zijin until December 2026 to shift mining operations to local contractors or face sanctions. Ghana revised local ownership rules in January 2025, requiring surface mining to be undertaken by fully Ghanaian-owned firms and underground mining by companies with at least 50% Ghanaian ownership. In addition, African governments have been tightening mining rules to extract more revenue amid rising metals prices.

For mining companies, these changes may support national development goals, but they can also raise costs, complicate contracting and increase uncertainty around long-term project economics. Royalty increases, local procurement mandates and ownership requirements can change the risk profile of projects, particularly for new mines that require major upfront capital. When those rules shift after companies have already invested heavily, the investment case can become more difficult to underwrite.

Illegal mining is another growing challenge. In Latin America, illegal gold mining is spreading into new parts of Peru’s Amazon, advancing along remote rivers and into Indigenous territories. Reports note that the expansion is accelerating deforestation, contaminating rivers with mercury and exposing remote communities to violence and organized crime.  In Brazil, billions of dollars of gold were being extracted illegally from the Amazon rainforest despite enforcement efforts.

These pressures strengthen the case for secure, transparent and infrastructure-supported gold development in the United States. Nevada remains central to that story. According to the U.S. Geological Survey’s 2026 gold summary, Nevada was the leading gold-producing state, accounting for about 64% of total domestic production. That makes Nevada not just a mining district but the foundation of U.S. gold supply.

This is where Lahontan Gold’s portfolio becomes relevant. The company’s Santa Fe Mine has historic production of 359,202 ounces of gold and 702,067 ounces of silver from open-pit mining with heap-leach processing between 1988 and 1995. Lahontan also reports a National Instrument 43-101 compliant indicated mineral resource of 1.539 million gold-equivalent ounces and an inferred mineral resource of 411,000 gold-equivalent ounces, all pit constrained.

Santa Fe’s brownfield profile is important in a market where new mines can face long timelines and uncertain permitting. Lahontan’s Santa Fe project is a 28.3-square-kilometer land package that includes 307 unpatented lode mining claims, 67 unpatented mill site claims and 24 patented lode mining claims. The company also notes that past production came from open pits processed by heap leach and reported recoveries of approximately 70% for gold and approximately 30% for silver. In addition, the company’s 2026 objectives include completing an updated mineral resource estimate and preliminary economic assessment, advancing mine permitting with the objective of commencing construction in 2027, continuing work at West Santa Fe and drill testing historic heap-leach pads to evaluate residual gold and silver mineralization for potential future reprocessing.

Those attributes are especially relevant as international hurdles rise. Existing mine infrastructure, historical production, oxide material and location in a leading U.S. gold state may give Santa Fe a different development profile than greenfield projects in jurisdictions facing royalty resets, local-content changes, illegal mining exposure and supply-chain uncertainty. Lahontan still faces the normal risks associated with exploration, permitting, financing and development, but its strategy is aligned with a broader market need for reliable Western gold supply.

As gold supply becomes more difficult to expand globally, the market may place increasing value on brownfield projects in stable jurisdictions with known mineralization and established mining histories. Lahontan Gold is seeking to occupy that space through Santa Fe and its broader Walker Lane portfolio. In a world where production in major countries is being pressured by safety reviews, environmental constraints, fiscal changes and informal mining risks, Nevada-based gold development could become more strategically important, and Lahontan’s work at Santa Fe positions the company as a powerful participant in that shift.

For more information, visit the company’s website at www.LahontanGoldCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the company’s newsroom at ibn.fm/LGCXF

Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals

  • Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics, with pharmaceutical companies continuing to commit substantial capital to preclinical and early-stage innovation.
  • The Jazz Pharmaceuticals–AbCellera collaboration illustrates how differentiated antibody technologies can command significant financial commitments before entering clinical development.
  • VERAXA Biotech AG is positioning its technology platform across both ADCs and T-cell engagers, two therapeutic modalities that continue to attract strategic partnerships and acquisitions.
  • Platform technologies and individual drug candidates both represent potential avenues for future partnering, licensing, and collaboration agreements.
  • Recent transactions across the sector demonstrate that pharmaceutical companies are actively seeking access to differentiated antibody engineering capabilities rather than waiting for late-stage clinical assets.

Biotechnology investors often focus on clinical milestones, regulatory approvals, and commercial launches. Yet in antibody therapeutics, some of the largest value-creating events occur much earlier. Strategic licensing agreements, research collaborations, and acquisitions, have become important catalysts for companies developing differentiated technology platforms, and have resulted in significant market value shifts. That trend has been particularly evident in antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics. Pharmaceutical companies continue to pursue external innovation as they seek new approaches for treating difficult cancers, creating an environment in which promising technology platforms can attract significant commercial interest well before pivotal clinical trials.

One recent example came from Jazz Pharmaceuticals and AbCellera, which announced a collaboration to discover next-generation multispecific T-cell engaging antibodies. Under the agreement, Jazz receives exclusive rights to develop and commercialize products emerging from the collaboration, while AbCellera is eligible for an upfront payment, research funding, development and commercial milestone payments that could total as much as approximately $2.7 billion, in addition to tiered royalties should products reach the market. The collaboration illustrates the scale of investment pharmaceutical companies remain willing to commit for differentiated antibody discovery capabilities even before clinical development begins, a flashing light for attentive investors (https://ibn.fm/kX2wa).

From an investor standpoint, the significance extends beyond the companies directly involved. The agreement reinforces the continued appetite among established pharmaceutical companies to secure access to novel antibody engineering technologies capable of generating future product pipelines.

The deal also demonstrates that this competitive environment is not limited to the largest global pharmaceutical companies. Jazz, while a substantial commercial oncology company, competes in an increasingly active market where companies across the industry are seeking innovative external technologies to strengthen future portfolios.

The same pattern has emerged in antibody-drug conjugates. Gilead Sciences recently agreed to acquire Tubulis, a German biotechnology company focused on next-generation ADC technologies, in a transaction valued at up to approximately $5 billion (https://ibn.fm/SwtCZ). Tubulis was founded around research originating from German academic institutions, highlighting how university-based scientific innovation can ultimately attract major strategic interest from global pharmaceutical companies.

VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, occupies a similar part of the innovation ecosystem. The company is developing a diversified oncology pipeline built around next-generation antibody therapeutics, including bispecific ADCs, bispecific T-cell engagers and engineered antibody formats predominantly based on its patented BiTAC platform. Rather than focusing exclusively on a single therapeutic approach, VERAXA is advancing multiple antibody platforms that could potentially support future collaborations across several oncology indications.

Its proprietary BiTAC platform reflects growing interest in increasingly sophisticated antibody engineering. As pharmaceutical companies seek therapies capable of improving efficacy while reducing off-target toxicity, bispecific antibodies, targeted payload delivery and immune cell engagement have become areas receiving sustained research investment.

This creates two potential strategic pathways that companies like VERAXA may pursue over time. The first involves platform partnerships similar to the Jazz-AbCellera collaboration. Large pharmaceutical companies increasingly license access to proprietary antibody discovery technologies capable of generating multiple therapeutic candidates over many years. These agreements frequently include upfront payments, research funding, milestone payments and future royalties tied to commercial success.

The second pathway centers on individual development programs. As drug candidates mature and generate additional preclinical or clinical data, pharmaceutical companies may pursue licensing transactions, co-development agreements or outright acquisitions focused on specific therapeutic assets.

Neither outcome is guaranteed when it comes to biotechnology development, with high risk being the unavoidable cost of high potential. Companies must continue generating compelling scientific data, expanding intellectual property portfolios, advancing manufacturing capabilities and meeting regulatory milestones before potential commercial partnerships become realistic. However, recent transactions demonstrate that pharmaceutical companies are increasingly willing to evaluate differentiated technologies well before products reach late-stage clinical development.

VERAXA appears to be building toward that position through continued investment in scientific validation, patent filings and development infrastructure. The company’s strategy of maintaining exposure to both ADCs and T-cell engagers aligns with two therapeutic categories that continue to generate significant pharmaceutical investment.

The broader transaction landscape reinforces this trend. Among recent ADC transactions, Pfizer entered a strategic licensing and collaboration agreement with Innovent Biologics valued at up to approximately $10.5 billion to co-develop multiple oncology programs. Eli Lilly acquired CrossBridge Bio to expand its dual-payload ADC capabilities, while Roche expanded its collaboration with MediLink Therapeutics around a B7-H3-targeted ADC. Earlier, Avenzo Therapeutics licensed DualityBio’s EGFR/HER3 ADC in a transaction that included milestone payments exceeding $1 billion.

Activity has also remained strong across T-cell-based immunotherapies. Eli Lilly announced plans to acquire Kelonia Therapeutics to strengthen its in vivo CAR-T platform. Gilead expanded its immunology portfolio through the acquisition of Ouro Medicines, including its BCMAxCD3 T-cell engager program. Candid Therapeutics also entered the market with substantial financing focused on developing T-cell engager therapies for autoimmune diseases.

Collectively, these transactions suggest that pharmaceutical companies continue to view antibody engineering as one of the most active areas for external innovation. While individual technologies differ, the willingness to commit substantial capital at relatively early stages reflects confidence that next-generation antibody therapeutics will remain central to future oncology development.

For VERAXA shareholders, the relevance lies less in predicting any single transaction than in understanding the commercial environment in which the company operates. Recent collaborations and acquisitions demonstrate that differentiated antibody platforms can attract significant strategic interest before reaching late-stage clinical development, provided they continue to generate compelling scientific evidence and demonstrate clear technological advantages.

For more information, visit the company’s website at www.Veraxa.com.  

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Delivers First Edge AI Intoxication Detection Kiosk Prototypes

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.

  • MindBio kiosks use artificial intelligence and voice analysis to detect potential intoxication and fatigue in workplace environments.
  • The company is targeting industries such as mining, aviation, construction, transportation, and law enforcement, where safety-sensitive operations require large-scale screening.
  • MindBio’s AI models have been trained on more than 50 million data points and analyze over 140 acoustic markers associated with impairment.
  • Prototype kiosks are entering testing, validation, and data-analysis phases, before broader commercial deployment.
  • The company is positioning this important new technology as a faster and less invasive alternative to traditional drug and alcohol testing methods.

MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company, has reached a new development milestone with the completion and delivery of its first prototype Edge AI Intoxication and Fatigue Detection Kiosks, advancing the company’s effort to commercialize voice-based impairment detection technology for workplace safety applications. According to a recent company announcement, the kiosks combine proprietary hardware and software designed to assess intoxication and fatigue through short voice samples analyzed by artificial intelligence (https://ibn.fm/cnaJn).

The prototypes have now entered a testing and validation phase that will involve collaboration with industry participants, speech specialists and software engineers. The objective is to refine the company’s predictive models and evaluate performance under real-world operating conditions before broader commercial deployment.

The launch comes as employers across multiple industries face increasing pressure to improve workplace safety while managing the costs and operational burdens associated with conventional drug and alcohol testing programs.

Traditional screening methods, including breathalyzers, saliva tests, urine analysis and laboratory testing, remain widely used but often require significant administrative resources, trained personnel and processing time. For large employers operating in safety-sensitive sectors, testing hundreds or even thousands of workers can create logistical challenges.

MindBio is pursuing a different approach. Rather than relying on biological samples, the company’s technology analyzes vocal characteristics that may change when an individual is impaired by alcohol, drugs or fatigue. According to the company, its artificial intelligence platform evaluates more than 140 acoustic markers and has been trained using a dataset exceeding 50 million data points collected through years of research.

The result is intended to be a rapid screening process that can be completed through a standard microphone, potentially reducing the need for more invasive testing while enabling organizations to screen large workforces efficiently.

MindBio’s initial commercialization efforts are focused on industries where impairment management is already a regulatory and operational priority. Mining operations represent a particularly attractive market. Many mines operate around the clock, employ large workforces and often function in remote environments where safety protocols are critical. Conducting traditional drug and alcohol testing at scale can be both costly and time consuming.

The company has also identified aviation, construction, heavy transportation and law enforcement as target sectors. These industries share a common need for rapid, scalable and repeatable screening processes that can help identify individuals who may require additional evaluation.

MindBio recently expanded its platform beyond intoxication detection with the addition of fatigue recognition capabilities, reflecting growing industry interest in managing fatigue-related workplace risks alongside substance impairment.

The kiosk deployment follows several recent developments within MindBio’s commercialization strategy. Earlier this month, the company announced the launch of Intox AI(TM), its lead enterprise software platform designed to detect alcohol intoxication, drug use and fatigue through voice analysis. The platform is intended to serve as the analytical engine behind future kiosk deployments and enterprise integrations.

MindBio has also filed patent applications covering aspects of its AI-powered voice analysis technology, reflecting management’s effort to build an intellectual property portfolio around the platform as commercialization advances.

The company is entering a market that continues to expand as employers adopt new safety technologies and regulators place greater emphasis on workplace compliance. Demand for impairment detection tools is being driven by industries where employees operate heavy machinery, manage transportation systems or perform other safety-critical tasks. Organizations are increasingly seeking solutions that can improve efficiency while maintaining testing standards.

MindBio’s strategy centers on providing a scalable screening layer that can be deployed at facility entrances, worksites and operational checkpoints. Workers provide a short voice sample, and the system generates an assessment within seconds. Those flagged for potential impairment can then undergo additional evaluation using existing testing protocols.

For more information, visit the company’s website at www.MindBioTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

  • Quantum BioPharma executive co-chairman and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast.
  • Durkacz outlined the company’s strategy for advancing Lucid-MS, the company’s lead drug candidate for multiple sclerosis.
  • The Quantum BioPharma exec also provided an update on unbuzzd, the company’s innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster.

Executive thought leadership has become an increasingly important component of corporate communications, particularly in highly specialized industries such as biotechnology. Through podcasts, interviews and other educational forums, company leaders can explain complex technologies, discuss development strategies and provide context that is often difficult to capture in traditional press releases. That approach was recently on display when Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) executive co-chair and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast.

Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative, metabolic and alcohol-misuse disorders, with Lucid-MS and its ownership in commercially product unbuzzd(TM). During the interview, Durkacz outlined the company’s strategy for advancing Lucid-MS, the company’s lead drug candidate for multiple sclerosis (“MS”); discussed the market opportunity for unbuzzd; and reviewed key objectives planned for this year.

Durkacz focused much of the discussion on Lucid-MS. Explaining the rationale behind the program, he noted that “Quantum BioPharma is focused on a drug candidate that is trying to address an issue that exists today for people that suffer from multiple sclerosis.” He went on to describe the progressive nature of the disease and the debilitating impact it can have on mobility and quality of life.

“What our main drug candidate focus, Lucid-MS, is trying to do is reverse damage that’s been done to people’s mobility,” he stated, noting that almost three million people are diagnosed with MS worldwide with almost one million in the USA. “We believe that is something that is not addressed in any drug or therapy today in the world.”

The podcast discussion also covered the company’s development plans for Lucid-MS, which includes an upcoming clinical trial. “We filed our IND for a phase 2 trial for MS patients,” Durkacz explained. Once approved, “This will be the first time that Lucid-MS would be taken by a person with MS.”

“This will be the first time we will be able to see the reaction . . . and determine whether there are any efficacy signals that match what we’ve seen in our animal models over the past decade,” he continued. “That is what we are laser focused on right now.” The advancement into patient studies marks an important milestone for the program as the company seeks to gather additional data regarding safety and potential life changing therapeutic effects.

In addition to discussing its therapeutic pipeline, the Quantum BioPharma exec used the interview to provide an update on unbuzzd, a product the company developed that has been licensed and was designed and clinically proven to accelerate alcohol metabolism. Durkacz explained that the product is already commercially available in the United States and forms part of the company’s broader strategy of building value through both clinical-stage biotechnology assets and commercial opportunities. The combination of therapeutic development programs and commercial products gives the company exposure to multiple potential growth drivers while advancing its longer-term pharmaceutical objectives.

Durkacz and podcast host Stuart Smith also discussed the company’s broader mission. The company is focused on developing innovative solutions for challenging neurodegenerative and metabolic disorders as well as alcohol-misuse conditions. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma continues to advance Lucid-MS. Meanwhile, the company maintains an ownership interest in unbuzzd Wellness Inc. and continues to participate in the commercial growth of the unbuzzd brand.

The BioMedWire Podcast focuses on conversations with executives and industry experts involved in pharmaceutical and biotechnology innovation. The format provides an opportunity for management teams to discuss scientific programs, business strategies and industry trends in greater detail than is typically possible through standard corporate communications.

As biotechnology continues to become increasingly complex and competitive, educational platforms such as podcasts are emerging as valuable tools for corporate communication. For companies developing novel therapies, direct discussions with knowledgeable executives can help investors, industry observers and potential partners gain a deeper understanding of both the science and the business strategy behind emerging innovations. Quantum BioPharma’s recent BioMedWire appearance illustrates how executive engagement can complement traditional investor relations efforts while providing a more detailed look at the company’s research programs, commercial initiatives and anticipated milestones for the year ahead.

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Rare Earths in 2026: Structural Deficits Open Ground for Junior Developers Like Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF)

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

  • The global rare earth elements market is projected to grow from roughly $14 billion in 2025 to more than $41 billion by 2034, driven by accelerating demand from EV traction motors, wind turbines, consumer electronics, and defense applications
  • China continues to dominate rare earth mining and processing capacity, leaving Western manufacturers exposed to persistent supply concentration risk as governments push to build alternative supply chains
  • Canamera Energy Metals raised approximately $10.2 million over four months ending March 2026 and is advancing active exploration programs across seven rare earth and uranium assets in Brazil, the United States, and Canada

The rare earth supply story has moved beyond long-term strategic concern and into immediate industrial planning. Electric vehicles, wind turbines, advanced electronics, and modern defense systems all rely on rare earth inputs that remain heavily concentrated in a small number of global supply channels. Demand projections continue to move higher, but bringing meaningful new supply online remains a slow and capital-intensive process. That imbalance is creating a widening opportunity for developers positioned in jurisdictions seeking to diversify critical mineral supply chains.

Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF) is operating within that emerging window, building a multi-jurisdiction portfolio of rare earth and uranium assets across Brazil, the United States, and Canada as Western governments and manufacturers search for alternative supply sources.

A Structural Supply Problem

The long-term rare earth demand thesis remains difficult to ignore.

Global rare earth elements market projections suggest the sector could expand from approximately $14 billion in 2025 to more than $41 billion by 2034, supported by broad-based growth in permanent magnet demand. Electric vehicle adoption remains a major catalyst, with each traction motor requiring rare earth magnet materials containing elements such as neodymium and praseodymium. Wind power infrastructure adds another major layer of demand, particularly offshore installations where magnet intensity is significantly higher.

Defense applications add further pressure.

Rare earth elements are essential in radar systems, missile guidance, communications infrastructure, and other advanced military technologies, making supply chain security a strategic issue rather than simply an industrial one.

Supply growth, however, operates on a different timeline.

China still maintains dominant control over global rare earth mining, refining, and magnet manufacturing capacity. While major Western players including MP Materials, Lynas, and Iluka continue building out alternative infrastructure, meaningful production diversification remains years away in many cases. New greenfield projects often require extended permitting timelines, technical de-risking, infrastructure investment, and substantial capital commitments before reaching commercial output.

That leaves a supply gap between rising demand and available Western production.

Why Ionic Clay Projects Matter

Not all rare earth projects are built the same.

Brazilian ionic adsorption clay deposits have become increasingly relevant because they may offer a potentially faster and less capital-intensive development pathway compared with traditional hard-rock rare earth operations.

In these systems, rare earth elements are loosely bound to clay particles near surface, allowing extraction methods that can be materially less complex than conventional hard-rock mining and processing routes. That distinction has attracted growing investor and industry attention as supply chain diversification becomes more urgent.

Brazil also offers additional advantages, including established mining infrastructure, favorable geology, and increasing strategic relevance in global critical minerals development.

That backdrop helps explain Canamera’s focus in the region.

Canamera’s Expanding Platform

Canamera is building exposure through multiple rare earth opportunities while maintaining geographic diversification across the Americas.

In Brazil, the company is advancing ionic clay-hosted rare earth exploration at Turvolândia and Patos. At Turvolândia, Canamera completed the initial 350-meter phase of a planned 1,000-meter auger drill campaign, with prior disclosed intervals exceeding 6,000 ppm total rare earth oxide, suggesting characteristics associated with ionic clay mineralization. The remaining program is underway, with assay results expected in the near term.

The Patos Project represents another Brazilian ionic clay opportunity currently undergoing due diligence drilling to support acquisition decisions.

Beyond Brazil, the company is advancing the Iron Hills critical minerals project in Colorado through 3D geophysical modeling while progressing uranium work at Great Divide in Wyoming.

Its Canadian portfolio adds further optionality.

Ontario-based projects including Schryburt Lake, Garrow, and Waterslide are each moving through technical studies, airborne surveys, permitting pathways, and early exploration programs.

That portfolio breadth is notable, but execution requires capital.

Canamera reported raising approximately $10.2 million over the past four months, giving the company financial flexibility to fund multiple active exploration initiatives while maintaining operational momentum across jurisdictions.

The Junior Developer Window

Large-scale rare earth supply diversification will likely be led by major producers and integrated processors. That is already happening.

But large-scale projects take time.

In the interim, junior developers with capital, active exploration programs, and strategically positioned assets may benefit from heightened industry attention, stronger funding conditions, and potential partnership interest as supply chain participants seek future sources of material.

Rare earth demand continues rising, supply diversification has become a geopolitical priority, and developers capable of advancing credible projects are operating in a market that increasingly values optionality.

For more information, visit the company’s website at CanameraMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMETF are available in the company’s newsroom at ibn.fm/EMETF

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document contains “forward-looking information” within the meaning of applicable securities legislation, including statements regarding: the Company’s planned exploration activities on its projects; the anticipated timing and completion of the earn-in milestones under the Option Agreement; the Company’s ability to make required cash and share payments and incur required exploration expenditures; the geological prospectivity of its projects; and the Company’s exploration strategy.

Forward-looking information is based on assumptions, estimates, and opinions of management at the date the statements are made and is subject to a variety of risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. These assumptions include, without limitation: the Company’s ability to raise sufficient capital to fund its exploration programs and option payments; favourable regulatory conditions; continued access to its projects; and general economic conditions.

Important risk factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to raising sufficient financing; the inherently speculative nature of mineral exploration; title risks; environmental and permitting risks; and fluctuations in uranium prices. Additional risk factors affecting the Company can be found in the Company’s continuous disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information.

American Fusion(TM) Inc. (AMFN) Files Additional Texatron(TM) Patent Application as Development Advances Toward Testing Milestones

  • American Fusion(TM) continues development of its 5MW pre-production Texatron(TM) Fusion Engine(TM) and is progressing toward planned testing activities in Texas.
  • Regulatory engagement with the Texas Department of State Health Services remains underway as the company advances certification and licensing requirements.
  • The company is expanding its intellectual property strategy to protect future innovations involving reactor architecture, plasma systems, and commercial deployment methods.
  • Through its wholly owned subsidiary Kepler Fusion Technologies, the company is developing multiple Texatron(TM) system designs aimed at modular energy deployment.
  • The company’s broader commercialization strategy focuses on scalable fusion systems for industrial, commercial, and grid-related energy applications.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, has filed an additional patent application as it advances the development of its Texatron(TM) Fusion Engine(TM) platform, marking another step in the company’s effort to build a portfolio of proprietary technologies around future fusion energy systems (https://ibn.fm/lIIYZ).

The new filing, U.S. Patent Application No. 19/701,742, relates to a fusion system architecture incorporating advanced housing and chamber design elements intended to support plasma confinement, pulsed energy delivery, and future commercial applications of the Texatron(TM) platform. According to the company, the filing represents part of a broader intellectual property strategy focused on protecting technologies developed during the evolution of future generations of the Texatron(TM) Fusion Engine(TM).

The announcement comes as American Fusion(TM) continues to advance its 5MW pre-production Texatron(TM) Fusion Engine(TM) program. Management reported that the system’s primary frame has been completed and that final modifications have now completed at a third-party manufacturing facility in the Midland/Odessa region of Texas. This Texatron(TM) is now safely back at the company’s homebase as preparations continue for future testing activities in the Dallas-Fort Worth Metroplex.

The company also continues to work through regulatory processes associated with planned testing. American Fusion(TM) submitted an application for certification and related approvals to the Texas Department of State Health Services in February 2026 and has reported ongoing engagement regarding licensing and certification requirements.

Beyond regulatory progress, current development activities include planning for testing facilities, acquiring specialized validation equipment, expanding the company’s patent portfolio, and establishing commercial deployment strategies for future Texatron(TM) systems. The company’s fusion strategy is being developed through its wholly owned subsidiary, Kepler Fusion Technologies.

Fusion energy remains an area of significant global research and investment because of its potential to provide long-duration, low-carbon electricity. Numerous companies are pursuing different approaches to achieving practical fusion systems, with varying engineering designs, fuel approaches, and commercialization timelines.

American Fusion(TM) is developing an aneutronic fusion approach through the Texatron(TM) Fusion Engine(TM) architecture. The company is pursuing a modular design strategy, with management indicating that multiple Texatron(TM) models are under development. According to comments from company leadership, the current development roadmap includes a 5-megawatt system intended to demonstrate the technology and several larger 10-20-30-50 and 100-megawatt designs that forms the foundation of its planned commercial-scale platform.

The modular approach is designed around standardized units that could potentially be combined to provide larger levels of power generation. For example, multiple 100-megawatt units could theoretically be deployed together to reach utility-scale energy capacity.

The company’s strategy emphasizes system engineering, intellectual property development, and creating architectures intended for long-term commercial operation. Management has stated that continued patent expansion is an important part of establishing competitive positioning as the technology progresses.

In a recent interview with Small Cap Stocks Today, Executive Chairman Brent Nelson discussed the company’s intellectual property strategy, regulatory progress, testing plans, and broader commercialization objectives. The interview formed part of the company’s ongoing effort to provide updates to investors and the market as development milestones are reached. 

“Intellectual property development, regulatory advancement, and execution of our testing roadmap remain core priorities for the company,” said Nelson. “We believe each additional patent filing strengthens the foundation of the Texatron(TM) Fusion Engine(TM) platform while supporting our broader commercialization strategy. At the same time, we continue advancing toward important testing and validation milestones that we believe will help define the next stage of the company’s development.”

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

From Our Blog

Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

September 22, 2026

Nearly three million people around the world wake up every day managing a disease that has no cure, and the number keeps climbing. That reality is what makes new approaches to multiple sclerosis worth paying attention to, and it is the space where Quantum BioPharma (NASDAQ: QNTM) is working to make a difference with its […]

Rotate your device 90° to view site.